Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors

Chemical Biology & Drug Design
Song ZhangBinghong Feng

Abstract

The synthesis and biological evaluation of a novel series of compounds based on suberoylanilide hydroxamic acid (SAHA) had been designed as potential histone deacetylase inhibitors (HDACis). Molecular docking studies indicated that our derivatives had better fitting in the binding sites of HDAC8 than SAHA. Compounds 1-5 were synthesized through the synthetic routes. In biological test, compounds also showed good inhibitory activity in HDAC enzyme assay and more potent growth inhibition in human glioma cell lines (MGR2, U251, and U373). A representative compound, N3F, exhibited better inhibitory effect (HDAC, IC50  = 0.1187 μm; U251, IC50  = 0.8949 μm) and lower toxicity for human normal cells (LO2, IC50  = 172.5 μm and MRC5, IC50  = 213.6 μm) compared with SAHA (HDAC, IC50  = 0.8717 μm; U251, IC50  = 8.938 μm; LO2, IC50  = 86.52 μm and MRC5, IC50  = 81.02 μm). In addition, N3F obviously increased Beclin-1 and Caspase-3 and 9 as well as inhibited Bcl-2 in U251 cells. All of our results indicated that these SAHA cap derivatives could serve as potential lead compounds for further optimization. In addition, N3F and N2E both displayed promising profile as antitumor candidates for the treatment of human glioma.

References

Sep 23, 2008·Cell Death and Differentiation·M C MaiuriG Kroemer
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ina OehmeOlaf Witt
Apr 7, 2009·Cell·Hyunkyung JeongDimitri Krainc
Sep 29, 2009·Expert Opinion on Investigational Drugs·Ina OehmeOlaf Witt
Dec 2, 2009·Journal of Chemical Information and Modeling·Gabriella OrtoreAdriano Martinelli
Mar 3, 2011·Journal of Cellular and Molecular Medicine·Jacob E ShabasonKevin Camphausen
Nov 15, 2011·Cell·Noboru Mizushima, Masaaki Komatsu
Oct 16, 2012·Expert Opinion on Therapeutic Targets·Geneviève P DelcuveJames R Davie
Jul 3, 2013·Seminars in Cancer Biology·Séverine LorinPatrice Codogno
Nov 23, 2013·European Journal of Medicinal Chemistry·Matteo PoriDaria Giacomini
Mar 14, 2014·Apoptosis : an International Journal on Programmed Cell Death·Zhen-Yu WangWen-Ge Liu
Apr 29, 2014·Pharmacology & Therapeutics·Prithviraj BoseSteven Grant
Sep 11, 2014·Pharmacology & Therapeutics·Ioannis AnestopoulosMihalis I Panayiotidis
Sep 23, 2014·Journal of Molecular Graphics & Modelling·Lan-Lan ZangRun-Ling Wang
Oct 17, 2014·Cell Death & Disease·Y KangR H Dashwood
Jan 9, 2015·The Journal of Experimental Biology·Michael Daniel, Trygve O Tollefsbol
Jan 22, 2015·The Journal of Biological Chemistry·Raushan K SinghD K Srivastava

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.